InSilicon Intelligence

Insilico Medicine is a generative artificial intelligence-poweredbiomedicaltechnology company focused on utilizing AI technology to accelerate the drug discovery process.

Company Overview

• Established: Insilicon Intelligence was first founded by Alex Zhavoronkov in 2014 at Johns Hopkins University in Baltimore, USA, and has since established a number of subsidiaries in China, including Insilicon Intelligence Technology (Suzhou) Co. Ltd. (established in 2021), Insilicon Intelligence Technology (Beijing) Co.
• Headquarters location: Although InSmart has several branches around the world, the exact headquarters location may change due to business development and strategic adjustments.
• Business ScopeWe are building an AI drug discovery platform that focuses on identifying novel targets and generating drug candidates with specific attribute molecular structures, primarily through self-developed Generative Adversarial Networks (GANs), Deep Reinforcement Learning (RL), pre-training models (Transformers), and other machine learning technologies.

technical strength

• Pharma.AI platform: Insilicon Intelligence successfully released Pharma.AI, a fully integrated end-to-end AI and robotic drug discovery system in 2022, which is composed of three main parts, namely Biology42, Chemistry42, and Medicine42, and covers the entire drug discovery process of target discovery, drug discovery, and AI, which is composed of Biology42, Chemistry42 and Medicine42, covering the entire drug discovery process, including target discovery, drug discovery and clinical trial prediction.
  • Biology42: Includes apps such as PandaOmics, Generative Biologics, Life Star 1, and more for identifying and discovering new targets.
  • Chemistry42: Includes Generative Chemistry, a generative chemistry platform, and Golden Cubes, a drug off-target evaluation module for rapid discovery and optimization of early-stage drug compounds.
  • Medicine42: It consists mainly of the predictive clinical trial module inClinico, which is used for modeling the probability of success in mid- and late-stage clinical trials.
• technological innovation: Insilicon Intelligence has also demonstrated its leadership in the application of AI technology by utilizing deep neural network (DNN) models to predict physiological age, using genomics data to read out aging-related targets or physiological age, and predicting the response status of targets to drugs.

Operational results

• drug development: Insilicon Intelligence has successfully identified a novel anti-fibrotic target, TNIK, and based on this, has launched its clinical candidate and core product, ISM001-055, a potentially world's first-in-class small molecule inhibitor for the treatment of fibrosis-related diseases such as idiopathic pulmonary fibrosis (IPF).
• clinical trial: ISM001-055 has demonstrated favorable safety, tolerability and pharmacokinetic (PK) profiles in Phase I trials conducted in New Zealand and China, and a multicenter, randomized, double-blind, placebo-controlled Phase IIa clinical trial has been initiated to evaluate its efficacy in China.

Markets and Cooperation

• marketplace: Insilicon Intelligence has partnered with many of the world's leading pharmaceutical companies to leverage their technology and development strengths to accelerate drug discovery and development efforts.
• Financing: Insyde Intelligence has completed several rounds of financing since its inception, including Series A, B, C and D, with rising post-investment valuations. These funds have provided strong support for the company's R&D and market expansion.

future outlook

• technological innovationInSilicon Intelligence will continue to plough into the AI pharmaceutical field and promote technological innovation and application landing.
• market expansion: As the drug development pipeline continues to be enriched and clinical trials advance, Insil Intelligence is expected to achieve more breakthroughs and results in the market.

In summary, as an AI-driven biopharmaceutical technology company, Insilicon Intelligence has demonstrated strong technical strength and market potential in the field of drug development. In the future, with the continuous progress of technology and growing market demand, Insilicon Intelligence is expected to become one of the leading companies in the field of AI pharmaceuticals.